Understanding how BRAF and its partners contribute to cancer
Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathway
['FUNDING_OTHER'] · DANA-FARBER CANCER INST · NIH-10897944
This study is looking at how a specific gene called BRAF, which can cause melanoma and other cancers when it has certain changes, works in the body and how new drugs that target this gene can help treat cancer better.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10897944 on ClinicalTrials.gov |
What this research studies
This research investigates the RAS/MAP kinase pathway, which is often activated in various cancers, particularly focusing on the BRAF gene and its mutations, such as V600E, that drive melanoma and other cancers. The study aims to clarify the regulation of BRAF and the pharmacological effects of drugs targeting this pathway, which can sometimes have unexpected effects. By utilizing advanced techniques like cryo-electron microscopy, the research seeks to uncover the structural and biochemical mechanisms behind BRAF's function and its interactions with other proteins, ultimately aiming to improve targeted cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients diagnosed with melanoma or other cancers associated with BRAF mutations.
Not a fit: Patients with cancers not related to BRAF mutations or those who do not have any mutations in the RAS/MAP kinase pathway may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for patients with cancers driven by BRAF mutations.
How similar studies have performed: Previous research has shown success in targeting similar pathways, indicating that this approach has the potential for meaningful advancements in cancer treatment.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ECK, MICHAEL J — DANA-FARBER CANCER INST
- Study coordinator: ECK, MICHAEL J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Cancer Cause, Cancer Drug, Cancer Etiology, Cancer Treatment